CJC-1295 (no DAC) vs TB-500
Both CJC-1295 (no DAC) and TB-500 are used for recovery. Here's how their evidence, dosing, and regulatory status actually compare.
CJC-1295 (no DAC)
Evidence BModified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
View full CJC-1295 (no DAC) profile →TB-500
Evidence BThymosin Beta-4 Fragment
A synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
View full TB-500 profile →Side-by-Side
| Attribute | CJC-1295 (no DAC) | TB-500 |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026) |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 2 mg twice weekly (subcutaneous) |
| Clinics Indexed | 156 | 183 |
| Categories | growth-hormone, anti-aging, recovery | recovery, anti-inflammatory |
Key reported benefits — CJC-1295 (no DAC)
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Key reported benefits — TB-500
- ✓Wound healing
- ✓Anti-inflammation
- ✓Tissue regeneration
- ✓Flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.